

▲ New York Blood Center Enterprises



IRL Experience:

MLS Rotation in the Immunohematology Reference Laboratory

Student Handbook

Required Pre-Rotation Modules

- Print out the handbook for this rotation.
- Access modules at www.nybc.org/educationresources
 - o Click on "Laboratory Science Student Resources"
- Complete the following modules and fill out the associated pages in this handbook:
 - Comparing Blood Bank Methods (p. 2-5 of this handbook)
 - o ABO Discrepancies (p. 7 of this handbook)
 - o DATs, Eluates and Rh Nomenclature (p. 9-14 of this handbook)
 - Warm Autoantibodies (p. 15-17 of this handbook)


Learning Objectives

- 1. Perform antibody testing using the three blood bank methodologies: Tube, gel and solid phase.
 - a. Describe how each methodology works to demonstrate antibodies in patient plasma.
 - b. Compare and contrast gel, solid phase, and tube testing in terms of procedure, interpretation, strengths and limitations.
- 2. Resolve ABO discrepancies.
 - a. Discuss causes of discrepancies and laboratory methods used to resolve discrepancies of various causes.
- 3. Perform pre-transfusion testing to rule out alloantibodies in a sample containing warm autoantibody.
 - a. Describe common reactions in a sample containing warm autoantibody.
 - Compare and contrast allo- and autoadsorption in terms of criteria for performing, choosing adsorbing cells, treatment of adsorbing cells, and limitations of the procedure
 - c. List transfusion options for patients with warm autoantibody.
 - d. Compare and contrast methods to determine the phenotype of recently transfused patients.

Comparing Blood Bank Methods

Use the "Comparing Blood Bank Methods" Module to review pages 2-4 and then to complete the chart on p. 5.


Solid Phase Red Cell Adherence Assay (SPRCA)




Solid Phase Red Cell Adherence Assay (SPRCA) continued

- Antigens coat the well
- Plasma is added to wells, incubated at 37C, antibodies (if present) attach to antigens
- Wash step: unbound antibody is removed
- Indicator cells (RBCs coated with anti-IgG) are added
- Centrifugation
- Interpretation: a tight cell button indicates a negative reaction, effacement of the cell button indicates a positive reaction

Gel (Column Agglutination Testing)







https://labs-inc.org/pdf/358_1.pdf

- Plasma and (0.8%) RBC suspension added to reaction chamber
- Incubation at 37C, antibodies (if present) attach to antigens
- Centrifugation pulls RBCs through gel that contains anti-IgG
- RBCs coated with antibody will get stuck in gel; RBCs without coated antibodies fall down to a pellet at the bottom of the column.
- Interpretation: RBCs stuck in the gel indicate a positive reaction; RBCs at the bottom of the column indicate a negative reaction.

Tube Testing



Tube Testing continued



Harmening DM. Modern Blood Banking & Transfusion Practices. 5th ed. Philadelphia, PA: F.A. Davis Company; 2005.

- Add plasma and cells to tube; spin and read for immediate spin phase (alternatively, incubate at room temperature before spinning and reading)
- Add enhancement media, if applicable
- Incubate at 37C. Following incubation, spin and read for 37C phase
- Wash
- Add antihuman globulin reagent (anti-IgG)
- Spin and read (may read microscopically)
- To all negative tests, add check cells. Spin and read. Check cells should produce positive result for valid test.

Comparing Blood Bank Methods

Complete this chart prior to arriving at CBC and come ready to discuss.

Methodology	What does a positive reaction look like?	What does a negative reaction look like?	Tests for IgG, IgM, or both?	Includes incubation at 37C (yes/no)?	Includes centrifugation (yes/no)?	Advantages of this methodology	Disadvantages of this methodology
Tube	Antibody coated red cells visibly agglutinate after adding anti-IgG reagent						
Gel	Antibody coated cells get stuck in gel matrix following centrifugation						
Solid phase	Indicator cells adhere to the surface of the microwell when antibody is bound to red cell antigens coating the microwell.						

Laboratory Testing: 3 Methods

The table below will be used to record results of testing at CBC.

		Tube Testing	<u> </u>	Gel
	IS	LIS	SS	Gei
	15	37C	IAT	IgG
Screening cell I				
Screening cell II				
Screening cell III				

SPRCA testing results will be recorded on a panel provided by the instructor.

ABO Discrepancies

Use the "ABO Discrepancies" Module to complete this page and come to CBC ready to discuss. Use the choices available in the boxes to explain and resolve the following ABO discrepancies. You may use any answer more than once or not at all. Please note: sometimes, there will be more than one possible explanation and/or more that one way to resolve.

Possible Explanations

Cold Autoantibody
Recent Transfusion
Cold reacting alloantibody
A subgroup with anti-A1
BMT (group A+ to O+)
Rouleaux
Immunosuppression

Ways to Resolve

Increase 22C incubation time of back type
Prewarm back type
Inquire about patient history
No further testing required
Saline replacement of back type
Warm wash front type
Increase plasma/cell ratio
Identify alloantibody
Test with anti-A1 lectin

	Fro	_	pe: Te	_	3		ck Ty patie	-		_	Possible Explanation	Ways to Resolve
	Anti- A	Anti- B	Anti- A,B	Anti- D	Rh Cont.	A ₁ cells	A ₂ cells	B cells	O cells	Auto Cont.	Explanation	Resolve
1	4+	0	4+	4+	0	1+	0	4+	0	0		
2	0	4+	4+	4+	0	4+	3+	1+w	1+w	1+w	•	•
3	0	0	0	4+	0	0	0	3+	0	0	•	•
4	4+	2+ ^{mf}	4+	4+	0	0	0	0	0	0		•
5	1+	4+	4+	4+	1+	4+	4+	4+	4+	4+		•
6	0	4+	4+	4+	0	4+	4+	4+	4+	0		
7	0	0	0	0	0	0	0	0	0	0		•

Laboratory Testing: ABO Discrepancies

Use the following table to record results on samples:

Testing Method		F	ror	nt Ty	ре				Ва	ck T	уре		Interpretation
(IS, 37C incubation,				P	Anti-								
saline replacement, etc)	Sample ID	Α	В	A,B	A1	D	Rh Cont	A ₁ cells	A ₂ cells	B cells	O cells	Auto Cont.	

DATs, Eluates & Rh Nomenclature

Use the "DAT, Eluates & Rh Nomenclature" Module to complete pages 9-14.

ame reasons ar	individual	might have	a nositive D	ΔΤ-

- •
- •
- •
- •
- •

What is an eluate?

The eluate procedure begins with WASHING the RBCs. What is the purpose of washing?

The "last wash" is tested as a control. What results are expected when testing the last wash? What if there are unexpected results?

Reactivity of the Eluate	Possible cause of the positive DAT
Nonreactive	
Panreactive, reactive with autocontrol	
Contains alloantibody	

At CBC you will prepare and test an eluate from the sample provided.

STUDENT HANDBOOK: IRL Experience
Study the following dry cases and determine the most likely cause of the positive DAT. Come to CBC prepared to discuss these cases.

Condition Cond				Cell# Rh-hr	Add	* f antigen s	Mode of	Patient Cells	11 RIRI	70 m	9 11	8 rr	7 17	6 f"r	5 r/r	4 Ror	3 R2R2	2 R1R1	1 RiwRi	Cell# Rh-hr				© Ortho-Cli	PARTOFT
					itional (status m	Reactiv	is ent	1	3	00	31	31	<u> </u>	9	30						L.J.		nical Diag	₹ 0
			1		Pells	ay have	Ť		3287			1										Cat		nosaca L	
	-					been		 			ļ	 										6		8	<u>下</u> 页
	-					ntigen: detern	မ	-	-	-	-	-					-	-				3.	,	•	
			\dashv	170	B	s wnic	C/A		+	-	-	<u> </u>						0	0	0	=	Ž	-	. 5 7 . 11 %	180
				е	Ŧ	n are o	ntiglot		+	+	+	+	+	+	+	+	0	+	+	Ф	Ξ	5	5.	100 A	್ಟ್
	-			128		ptivel	uli m		 			 	ļ						,			- #V			ਨਿੰ
	-	-	+			y base	-	-	-		 	 										1 1	1 9 3		i (S
	-		-		K	d on F	-	┼	-		-		-				_							7. 6	
			\dashv	~		Ssed b		-	 									-		∽.		t-control			
3 CUT ST				Kpa	Ā	y enz) whenoty			0	0	0	0	٥	0	0	٥	0	0		Κpa	Kaj				
			_	ξ _i	-	me tre		ļ		-	<u> </u>	-		+						Ag Ja	F		5	DATE	PAT
	-		-	sa, Js		atmer	ntigle	-	 			ļ	-	,						s _{at}		4	j		1 1
				F _V	9	7	bulin	3.435	 		ļ	 	-							-Ty	9		7	2	? \$
TECH: TUTIEUW TUTIEUW TELWIS TECH: TUTIEUW TUT		· *		Fγb	₹) II =	•	7/16/	9 + 3	0	0	+	.+	+	0	0	*	٥		Ą	Ŧ	-			1 1
Panel Reagen Reagen Resolve Reagen Reagen Resolve Reagen Resolve Resolve Resolve Resolve Resolve Antigrar Resolve				Jka .	Ē	lesults			0	+	+	٥	+	+	+	+	0	+	+	Jka	Ē				1 2
Panel Reagen Reagen Resolve Antigrar LEWIS MINS P UNITERAL Antigen Typin (ge Lee Leb S s M N P, Lue Lub + + 0 0 + + + 0 0 0 + + + + 0 0 0 + + + 0 0 0 + + 0 0 0 + + + 0 0 0 + + 0 0 0 + + + 0 0 0 + + 0 0 0 0				장	0	s thos are fr		2000.000	-				. 62022.00							충				- 1	1 5
Panel Reagen Resolve Antigrar Levis MNS P Luneral Antigen Typin Special Lub O + + + + 0 + 0 + + + + 0 + + 0 O 0 + + + + 0 + 0 + + + + 0 O 0 + + + + + + + 0 + + 0 O 0 + + + + + + + + + + + + + + + + + +		1.00 8	/## E	(ga ⊢		e antig om his	.	4555	-	300 700	345. 2		193.3	3522 . 14				145,55	2500	G _a	700 March			TEC	
Panel Reagen Reagen Resolve Antigrar New Reagen Resolve Reagen Antigrar Indian I			+	e ^a Le	SWE	jens w storica	√a	-	-				-							e Le					100
Panel Reagen Resolve Antigrar NNS P LUM-LUB Antigen Typin S M N P1 Lu-LUB Antigen Typin Cold Var. Cold Var. Cold Var. Cold Var. Cold Var. Cold Lu-LuB S M N P1 Lu-LuB S M N P1 Lu-LuB LuB LuB Cold LuB LuB Special Antigen Typin		8 A B				hose p	riable	45%	170	-9007-07	0	200.	ъ		0	0	0	+	0			1			C
Panel Reagen Resolve Antigrar M N P ₁ Lus Lub Antigen Typin M N P ₂ Lus Lub Antigen Typin M N P ₃ Lus Lub Antigen Typin M N P ₄ + + + + + + + + + + + + + + + + + + +	1378			550	3	g. "/" r			1	0	7,000,000	20000-00	+	7.5	1000	2422	+	0	Will have no	10000	MN				
Panel Reagen Resolve Antigrar V P1 Lus Lub Antigen Typin + + + + + + + + + + + + + + + + + + +					7 7	xe or al eprese	Q	2/22	-		51,59±5+18	#374 B	520,000					1000	1980/1971	17.00.00					1
Panel Reagen Resolve Antigrar Lus Lub O + + + + + O + + + + + + + + + + + +		1 2 3 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	_	Ъ		nts "N	윱	17.5%	-			-	110,100,00			******	1-12/32/02								
Panel Reagen Resolve Antigrar Lub Antigen Typin Lub Antigen Typin Lub Antigen Typin Lub Antigen Typin						may h	_	-						.,	2.5						Local de	l			
Reagen Reagen Antigrar Antigrar Antigen Typin,			\dashv	ua Lı		ted" fo	Var.		-			 								ua Lt	UNER				Pa
Reagen Resolve Antigrar Special Antigen Typin, onors. Special Antigen Typing a sing special Antigen Typing and sing special Antigen Typing and sing special Antigen Typing special Ant			\dashv	<u>_</u>		een det	-		<u> </u>	7						7	7	-	T	ŢĠ.					ne
	escretos som cas de circular de marco de como			Amger Typin	Special Antigen Typing	ermined using a sing onors.															Special Antigen Typing		Antigrar	Resolve	
					-20000000	a spec	un Baldis	27	ħ	25	3	ž	よ	¥	7	¥	ゟ	۲¢	24		- IAT		en f	A S	
Celle College A A A A A A A A A A A A A A A A A A			+	-	Teg	affic ani	-	دن	دن	w	درن	دن	(س		/ 1-1	دن	در ب	دن	در	acia	/ 5 /ω	te.	rofi	Ğ) s
Reagent Red Blood Cells Resolve® Panel A Antigram® Antigen Profile Special igen Typing Cell J Test Results 1 24 34 34 34 34 34 34 34 34 34 34 34 34 34					Test Results	DRT use		22. X.A.	*	ギ	-34·	ナ	7	Ť,	み	4"	さ	7	*	OCTO PEG (P	Test Results	, -		00062	CCYY-MM-DD

			8		Shadev *fantiç	Moc		:	a	6	6 6	7	•	GF.	4	త	N	-	\$ \$		e Pag
			Rh-hr	Additio	d columi	Mode of Reactivity	Patient Cells	RIRI	7	7	17	П	7	7	Ror	R2R2	R1R1	R1wR1	Rh-hr	V + 1/2	rthc
			Donor Number	Additional Cells	Staded columns indicate those antigens which are destroyed or depressed by enzyme treatment. I antigen status may have been determined presumptively based on Rh-hr phenotype.	activity		23287	311014	84368	312943	310235	312950	311903	306104	308217	312609	312962	Donor Number		Ortho Clinical Diagnostics PART OF THE Johnson Johnson Fabrity or COMPANIES CONTO-Chical Diagnostics, Inc. 2010
			0		ave be			+	0	0	0	0	0	. 0	+	+	+	+	0	Parket Face Long Marginal Registers The Control of	
		<u> </u>	0		se anti sen de			+	0	0	0	0	0	+	0	0	+	+	C		
			т		gens	37°		0	0	0	0	0	+	0	0	+	0	0	m	PP-1	Diagnostic
			c	Rheir	which ned p	37°C/Antiglobulin		0	+	+	+	+	+	+	+	+	0		c	Rh-fr	9
			Ф	-	are d	tiglob		+	+	+	+	+	+	+	+	0	+	+	0	•	SO ::
-			*		estroy ptivel	를		0	+	+	+	+	+	+	+	0	0	<u> </u>	*		16
-	-	-	Ç Ç		ed or y base			0	0	0	0	0	0	-	0	0	0	. +	Ç		* V/
			+		depre	-		0	0	0	0	0	0	•	+ 0	0 (٥	0	<u><</u>		
-			⊼ ⊼		Rh-h			+	+	+	0 +	+	+	0 +	+	0 +	o +	0 +	×		
-			₹	Δ.	by en			0	0	0	0	0	0	0	0	0		0		<u>a</u>	
		-	α Κρ	KELL	otype.			+	+	+	+	+	+	+	+	+	+	+	Қра Қр ^а	KSI	PATIE PATIE DATE: CONCI
			Kpa Kpb Jsath		treatr	Anti		0	`	0	_	_	`	_	. 0	0		`	Sa,		PATIENT ID: PATIENT ID: DATE: CONCLUSION:_
			Jsbt		nent.	Antiglobulin		+	+	+	+	+	+	+	+	+	+	+	Jsbt		
	17.4		Fya Fyb Jka Jkb	Purp		3	<u> </u>	0	4.5	+	+	0	0	0	0	0	+	+	Fy ^a Fy ^b	QUI Y	Z K
14			\rightarrow{\right		¹ Ind			+	0	0	***	+:	**	0	00	+	0	+		٧,	
_		-	Za	Ē	sults a		<u> </u>	0	+	.+	0	+	+	+	+	0	+	+	Jka Jkb	g	
<u></u>			κ ^b Xga		those		Servada	+	+	0	+ :4:	+	+ +	+	0	*	+	٥	κ _b Xg ^a	₹r.	To the part
	11-62	新城	ga Le	Linked LEWIS	antig		40.45842 40.45842	0	•	0	0	+	0	0	0	0	0	+		1005055000	
			Lea Leb		ens w	٧a		+	+	0	+	0	+	0	0	+	+		Lea Leb	LEWIS	H. H.
		57差	တ		hose p	Variable		+		0	+	0	0	0	0	6	4	0	တ		
-12%	is its		w	3	ig. "/"			+	0	+	0	+	+	+	+	•	0	+	Ø	N.S.	
	数额		Z	WIS	ce or			0	+	0	+	+	0	+	0	+	+	+	Z	Ø	
	80.5		z		absen ents '	Cold		+	0	+	0	+	+	+	•	0	0	+	z		
				•	Not T			+	+	+	+	0			+	+	0	0		٠,	
			L _a	LUTHERAN	y have ested"	Var.		+	0	٥	0	0	0	0	0	0	+	0	Lua Lub	LUTHERAN	ַ ד
			լսե	畫	been for ne	.5		+	+	+	+	+	+	+	+	+	+	+	Ê	ra _e	Panel
					^T Indicates those antigens whose presence or absence may have been determined ^ Results are from historical testing. "/" represents "Not Tested" for new donors.						0	0	0	@							<u>v</u> > 11 11
				Special Antigen Typing	iined usi ors.															Spe	Reg
				Typi	ng a si															Special igen Typing	eage solv
				ηĞ	ingle e															[B]	e® F
					xamp															<u> </u>	led Par
			8		le of a			=	ē	6	•	٦	6	Ø	4	ß	2	-	<u>.</u>	lige	Blo Blo
			L		spec		4	ñ	ず	ðž	₽ _x	₹	%.	₹.	ゲ	父	か	¥	PE6	<i>(A</i> = 1	o d
-			-	Teg	using a single example of a specific antibody.															Special Special Strain Special Strain Special Strain Special S	Reagent Red Blood Cells Resolve® Panel A
				Test Results	ibody.															t Res	ccyy-MM-DD Cells
				sults	•			0	0	್ಲ	0,	Ç	O.	9.	्	0	Q	Q	arcie Elva	Test Results PEG (47 635	800062
1								-	<		->		-	_	\rightarrow			-			

	Cell# Rh-hr	Adc	Shaded columns indicate those antigens which are destroyed or depressed by enzyme treatment. 'I antigen status may have been determined presumptively based on Rh-hr phenotype.	Mode of Reactivity	Patient Cells	11 RIRI	10 п	.	8 п	7 11	6 r"r	5 r'r	4 Ror	3 H2F12	2 RIR1	g RiwRi	Cell# Rh-hr				© Otto-Christol Diagnosias, Inc. 2010	Ortho Clinical Diagnostics
		Additional Cells	lumns inc status ma	f Reactiv	ient		31	Óο	312	31	312	311	306		312609	R1 312	hr Donor Number	i di		e de la companya de l		Įσ FΩ
	Donor Number	èlls	dicate thay have	₹		23287	311014	84368	312943	310235	312950	311903	306104	308217	_				* 1			l Tic
	0		been a			+	0 0	0 0	0	0	0,	0 +	+ 0	+	+	+	D C				8 8	- 22
	Е		ntigens detern	37		0	0	0	0	0	+	0	-	+	0	0	m-			· · · · · · · · · · · · · · · · · · ·		
	c	Rhin	s which	37°C/Antiglobulin		0	+	+	+	+	+	+	+	+	0	0	С	Ph-H	- 1			9
	Ф.	Ħ	h are o presun	ntiglot		+	+	+	+	+	+	+	+	٥	+	+	е	=		å		8
	<u>_</u> ,		destro nptive	din		0	+	+	+	+	+	+	+	0	٥	•	*					ਜ
	Cw V		yed or ly base			0	0	0	0	0	0	0	0	0	0	+	Ç₩ <1					· v
	ς,		ed on o	-		+	0 0	0	0 0	o +	0	0 0	+	0 0	0	-	7		* *.			
			Rh-hr			+	+	+	+	+	+	+	+	+	+	+	~					
	k Kpa Kpb Jsa ⁿ	쥬	by en: phenc			0	0	0	0	0	0	0	0	0	0	0	Кра Крь	KETT		100		
	र्हे	KELL	zyme (xtype.			+	+	+	+	+	+	+	+	+	+	+	즇	F			DATE:	PATIENT ID:
	Jsa⁺^		treatm	Antic		0	`	٥			^		0	٥		`	JSa ^{1*}		4		<u>c</u> i	
	Jsbi I		ent	Antiglobulin		+	+	+	+	+	+	+	+	+	+	+	Jsb† F	Z		1	Sion	₽ ₹
	Fya Fyb Jka Jkb Xga Lea Leb	PUFFY				• +	+	+	+	0 +	0 +	0 0	0	+	+ 0	+	Fya Fyo	DUFFY				
	\ S		' Indic	*		-	+	+	0	**************************************	T.: +	+	+	0	+	+	کر				1 : 17	14
	<u>۾</u>	ĝ	ults ar		-	+	+	0	+	+	+	0	0	+	+	0	Jka Jkb	ē				
. Jan. 1985.	×	₽ g	e fron			0	.+	74	i (+ ;	•	+	€ + ·	+	+	0	<i>*</i>	ď	ξg				
	Le _a	KIDD Linked LEWIS	antiger 1 histo	-	100000	0	0	0	0	+	0	0	0	0	0	+	Le ^a Le ^b	LEWIS			I CH	
		Wis	rical te	Variable		+	+	0	+	0	+	0	٥	+	+	0	-					
	S		se pre	ble		+	+	0	+	0	0	0	0	0	+	•	S					
	s	NINS	"/" re	-	400	+	0 +	+	0 +	+	+	+	+	+	+	+	8	NAS.				
	≤ z		preser	Cold		+	0	+		+	•	+	+	0		+	z					
	יי_		nts "No	ā	5.9966	+	+	+	+	0	*	÷	+	+	0	0	_70					
		70 E	may r	.	-	<u> </u>		_	-				_	-	-	0	F					
	Lu ^a Lu ^b	LUTHERAN	Indicates those antigens whose presence of assence may have been determined A Results are from historical testing. "/" represents "Not Tested" for new donors.	. Var.	-	+ +	+	0 +	0 +	0 +	+	+	+	+	+	+	Lua Lub	LUTHERAN				Panel
	<u>-</u>		r new	-	-	+	 	 ' -	(e)	· •	0	®		<u> </u>	<u> </u>							<u>8</u>
		,	donon															≥				
		Special Antigen Typing																Spe Antigen			Res Ant	Rea
		n Typ	ng a s															Special gen Typing		•	igra igra	ıgeı
		ā	ğiği															G			m _® −	nt H
			examp															Birth Inne		-	Resolve® Panel A Antigram® Antiger	ed
	8		ie ci	-		13	ā	•	c.	7	•	55	4	ဖ	l.	-	8			4	iel.∧	Blo
			speci	<u> </u>	#	5	5	2	2	2	5	20	0	5	0	5	PEE	IAT			ם ק	pd C
 	-	Ę,	using a single example of a specific aniabody.	[-	-	-	-	-	ľ		-	├		-	-	+	Test		•	Resolve® Panel A Antigram® Antigen Profile	Reagent Red Blood Cells
	-	Test Results	iooy.	-	+	+		-			-		 	<u> </u>	-	<u> </u>		Test Results-√			Œ	èlls
	1	its		-		7	0,	Q	ę	4	4	0,	8	¥	Ş	Q	29%	15 c	PE6 11	97 B	3580006	2

		Cell#	, p	Shaded * f antige	Mode	_ T	=	10 r	9	65 -	7	6 r [*] r	55 74	4 A	e B	ю П	A	Cell#			ŝ] C
		Rh-hr	Addition	column en statu	Mode of Reactivity	Patient Cells	R _R 1	-,	_	_	·	4		Ror	R2R2	RIRI	A1wA1	Rh-hr		**************************************	0	į
		Donor Number	Additional Cells	Shaded columns indicate those antigens which are destroyed or depressed by enzyme treatment. I antigen status may have been determined presumptively based on Rh-hr phenotype.	activity	-	23287	311014	84368	312943	310235	312950	311903	306104	308217	312609	312962	Donor Number		1	©Otto-Circui Dagnostos, Irc. 2010	OI LIO CIIIICAI DIAGNOSTICS
	 	0		those			+	0	0	0	0	ο.	0	+	+	+	+	D.			Ī	1 2
		С		en det	:		+	٥	0	0	0	0	+	٥	. 0	+	+	C			. 8	1 E
		E	-	ens w	37°C/Antiglobulin	-	0	0	0	0	0	+	0	0	+	0	0	m	20			1 28
		Се	Ribbir	hich a ed pre	/Antic		+	+	+	+	+	+	+	+	+	0 +	+	C e				18
		_*		re des sumpti	lobuli	-		+	+	+	+	+	+	+	0	0	0	- ,		y Y		1 2
		Ç		troyed vely b) >		0	0	0	0	0	-	0	. 0	0	0	+	Ç				18
		<₁		or de ased o			0	0	0	0	0	0	0	+	٥	٥	0	<u><</u>			i i	
		×		presse on Rh-			+	0	0	0	+	0	0	0	0	٥	0	7		·		
	-	. <u>~</u>		and by o			+	+	. +	+	+	+ .	+.	+	+	+	+	<u>⊼</u>		announced to the con-		
		p _a K	KEL	notyp		-	+	+	+	+	0 +	+	0 +	+	0 +	0 +	+	- S	Ã.		Σ.	g <u>y</u> :
_	+	k. Kpa Kpb Jsa ^t		e trea	3	-	0	_	0			-		0	0	,	_	Kpa Kpb Jsath Jsbt			CONCLUSION:	PATIENT ID:
		J _S b†		tment.	Antiglobulin		+	+	+	+	+	+	+	+	+	+	+	હ્યું			USIC	8
45		\Z̃	B		Julin 1	100	0) 	+	, r + 1:	ಂ	0		0		+	+	Fy _a Fy _b	DUFFY		ž: 	
.a. 99		Ŷ	PAHING	. A∈ . [17	+	18/4/2	1949	0	0	+	(+)	+	. 0	0	14	0	+	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\				11
		₹a		sults.		<u> </u>	0	+	+	0	+	+	+	+		+	+	Jka Jkb	ğ			
		Fya Fyb Jka Jkb Xga	5.6	s those are fro		100	+	+	+	+	*	+ #	+	•	+	+	o +	κ _δ Xga			7	
<u>-5, 92</u>		galle		e antig om his			0	0	0	0	+	0	•	0	0	0	+	투	Linted LEWIS			TECH:
	+	Lea Leb	KIDD Linked LEWIS	ens with	Vai		+	+	0	+	0	+	0	0	+	+	0	Lea Leb	SIME			
48 ES	188	S		hose p	Variable	1/4	+	+	0	+	0	0	•	0	0	4	ေ	Ø				
		σ	MNS	g. "/" I			+	0	+	0	+	•	+	+	+	0	+	Ø.	NINS S			
		X	ΰ	epres			0	+	0	+	+	0	+	0	+	+	+	Z	,			
Ren E		Z _D		ents "N	()	2/3	+	+	+	+	+	+ + *	+ *	+	+	0 0	+	_P				
			-	e may dot Tes			T			<u> </u>	Ľ	· · ·							2			, ,
	-	Lu ^a Lu ^b	LUTHERAN	sted" fo	Var		+	0	0	0	0	0	0	0		+	+	Ша Lub	LUTHERAN			D a
-	-	Ē	氢	oeen d or new	-	1	+	+	+	+	9	+ ®	+ @	+	+	+	+	16				Panel
- Carlotte and Car			>	Indicates those artispens whose presence or absence may have been determined using a single example of a specific antibody. A Results are from historical testing, "I" represents "Not Tested" for new donors.						9	1 189	(8)	(8)						2			
			Special Antigen Typing	ned usi	-														Special Antigen Typing		Anti	Res
			ecial Typi	ng as,															Special igen Typir		igra	yolve 19ger
			ηĞ	ingle e	-														ď		m®	ÿ⊚ T T
				xampk							736000	S-Sille	Marian.					O			Antigram® Antigen Profile	Reagent Red Blood Cells Resolve® Panel A
		<u></u>		of a s		Ž	さる	10	• ()	0	7	6)	€ ₹	0	S	かる	رې د	₽ 	(AT		gen	¥ 80 .
		-		pecific		+~	1	-		 	_	-	``			~	~	1			Pro	Ö
	1		Test F	antibo															est R		ofile	ells
			Test Results	Ŷ.		1	-	Ļ										ļ.,	Test Results		63580	1000
			S.		<u> </u>	-	0	3	32	3	0	0	.0	0	0	ヹ	^{برن}	elve	te PEC	IAT	035801	1002

Rh Nomenclature

After completing the online module, complete the table below.

Common Rh	Common Rh Haplotypes										
Fisher-Race	Wiener										
DcE											
DCe											
	R ₀										
	r										
dCe											
	r"										

Warm Autoantibodies


Use the "Warm Autoantibodies" Module to complete pages 15-17.

What are typical reactions for samples containing a strong warm autoantibody?

Test		Positive or Negative?
Antibody Screen		
Antibody Panel		
Autocontrol		
DAT	Polyspecific	
	Anti-IgG	
	Anti-complement	
	Saline Control	
Eluate		

^{**}Prepare and test an eluate from the sample provided.

How are clinically significant alloantibodies to common red cell antigens ruled out in cases of warm autoantibodies that react with all cells tested?



List 2 criteria for performing autoadsorptions

1.

2.

What is ZZAP? Why do you ZZAP autologous cells prior to adsorption?

When we perform <u>allo</u>adsorptions, we typically use a cell that is phenotypically matched to the patient.

- Describe what we mean by "phenotypically matched."
- Why do we use phenotypically matched RBCs for adsorbing cells?

What is the biggest risk when doing alloadsorptions?

Why do you ficin-treat adsorbing cells? (Give two reasons)

1.

2.

Which adsorbing cell would you use for performing alloadsorptions for patients with the following phenotypes? (Adsorbing cells are ficin-treated) Choose the correct cell(s).

Adsorbing cells available:

Adsorbing Cell A= R₁R₁, K-, Jk(a-)

Adsorbing Cell B= R_1R_1 , K-, Jk(b-)

Adsorbing Cell C= R₂R₂, K-, Jk(a-)

Adsorbing Cell D= R_2R_2 , K-, Jk(b-)

Adsorbing Cell E= rr, K-, Jk(a-)

Adsorbing Cell F= rr, K-, Jk(b-)

3.
$$R_2R_2$$
, K-, Fy(a-b+), Jk(a+b+), S-s+

STUDENT HANDBOOK: IRL Experience
How do you obtain a phenotype if the patient has been recently transfused?

Hypotonic Wash:
Principle:Limitations:
Molecular Phenotype
o Principle:
 Limitations:
The information below will be covered during your rotation at CBC.
Name 3 options for transfusion of patients with warm autoantibody and no underlying alloantibodies:
1.
2.
3.
Will crossmatches be compatible?

Procedures

Solid Phase Ready Screen Procedure

- 1. Add two drops of LISS to each well.
- Add one drop of positive control to the positive control well. Add one drop of negative control to the negative control well.
- 3. Add one drop of patient plasma to each of the testing wells (the purple color of the LISS will change to blue).
- 4. Incubate at 37C for 20-60 minutes.
- 5. Wash wells 4 times.
- 6. Add 1 drop of indicator cells to each well.
- 7. Centrifuge. Refer to job aid for centrifugation specifications.

Gel Testing Procedure

- Visually inspect gel card and verify the presence of gel and liquid layer above the gel. GEL CARD MUST REMAIN UPRIGHT. Label the card appropriately. Remove the foil from only the wells you will be using.
- 2. Add 50ul of 0.8% RBC suspension to each appropriate well. The RBC suspension should remain in the upper reaction chamber.
- 3. Add 25ul of patient plasma.
- 4. Incubate gel card(s) at 37C for 15 minutes.
- 5. Centrifuge the gel card for 10 minutes. Read, record, and interpret results.

Tube Testing Procedure

- 1. Label sufficient tubes for each cell tested.
- 2. Add 2 drops of plasma (or eluate/or alloadsorbed plasma) to each tube.
- 3. Add one drop of panel cells or autologous cells to appropriate tubes.
- 4. Add 2 drops of PEG (or LISS), mix, and incubate at 37C for 10 minutes.
- 5. Wash 4 times. Add 2 drops of anti-IgG.
- 6. Centrifuge. Read and record results. Check all negative reactions microscopically.
- 7. Add 1 drop of check cells to all negative tubes.
- 8. Centrifuge. Read. Make a check mark beside the IAT result if positive.
- 9. If negative, repeat IAT procedure.

ABO/Rh Typing

- 1. Label tubes for front type (anti-A, anti-B, anti-D, Rh control- test anti-A,B and anti-A1 only if necessary to resolve discrepancy) and back type (A₁ cells, A₂ cells, B cells, O cells, autocontrol)
- 2. Add 1 drop of the corresponding antisera into the front type tubes.
- 3. Add 2 drops of patient plasma to each back type tube and 1 drop of patient cells to each front type tube.
- 4. Add 1 drop of corresponding reagent red cells into the back type tubes.
- 5. Centrifuge for 15 seconds and read.

Eluate Procedure (using acid eluate kit)

- 1. Wash patient cells one time with saline. Wash 4 additional times with Working Wash Solution.
- 2. Remove the supernatant from the last wash, saving 1 ml from just above the red cells. Place in a tube labeled "last wash."
- Add 20 drops of Eluting Solution to 20 drops of washed red blood cells. Gently invert the red cells 4 times to mix.
- 4. Immediately centrifuge for 45-60 seconds.
- 5. Transfer the eluate to a clean 12X75 tube.
- 6. Add Buffering Solution until the eluate turns pale blue.
- 7. Mix and centrifuge eluate to eliminate debris. Transfer to a clean 12X75 labeled tube.
- 8. Test the last wash against antibody screening cells and the eluate against a panel by PEG IAT. If reactivity is detected in the last wash, prepare a new eluate after washing the cells more times with Working Wash Solution.

Procedures continued

Alloadsorption Procedure

The number of adsorptions needed to remove the autoantibody is equal to the antibody strength (i.e. an autoantibody reacting 2+ is adsorbed 2 times.)

- 1. Prepare 2 ml aliquots of appropriate ficin-treated adsorbing cells. Wash until the supernatant is clear.
- 2. On the last wash, centrifuge for 3 minutes. Remove as much remaining saline as possible (use small glass pipet).
- 3. To the tube of adsorbing cells, add 1 ml of patient plasma.
- 4. Mix and incubate at 37C for 10 minutes.
- 5. Centrifuge the tubes for 3 minutes.
- 6. Carefully remove the plasma and add to the next tube of adsorbing cells.
- 7. Repeat steps 2-4 as needed.
- 8. After final adsorption, remove the serum/plasma and place it into labeled tubes.
- 9. Test the alloadsorbed plasma against a panel by LISS IAT.



▲ New York Blood Center Enterprises

New York Blood Center Enterprises has multiple divisions across the country:

- New York Blood Center, located in New York City, NY
- Rhode Island Blood Center, located in Providence, RI
- Blood Bank of Delmarva, located in Newark, DE
- Community Blood Center, located in Kansas City, MO
- Memorial Blood Centers, located in St. Paul, MN

Come work for one of our Immunohematology Reference Labs or Genomics Labs!

Grow professionally within a world-renown organization.

For job opportunities for MLS graduates:

▲ New York Blood Center

https://www.nybc.org/about-us/work-here/

a Rhode Island Blood Center

https://www.ribc.org/about-us/careers/

Blood Bank of Delmarva

https://www.delmarvablood.org/about-us/work-here/

Community Blood Center

https://savealifenow.org/work-here/careeropportunities/

Memorial Blood Centers

https://www.mbc.org/about-us/careers/

innovation • experience • expertise